Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 06

447P - Clinical characteristics of 21 patients with type 1 diabetes mellitus related to immune checkpoint inhibitors

Date

03 Dec 2022

Session

Poster viewing 06

Topics

Immunotherapy

Tumour Site

Presenters

Haruna Kameoka

Citation

Annals of Oncology (2022) 33 (suppl_9): S1598-S1618. 10.1016/annonc/annonc1135

Authors

H. Kameoka1, J. Tauchi2, K. koshiba3, M. Uoi4, D. Hisamatsu4, A. Miyada1, S. Takada5, T. Hiromasa5, R. Matsui2, K. Ohashi6, T. Kawasaki7

Author affiliations

  • 1 Department Of Pharmacy, National Hospital Organization Shikoku Cancer Center, 791-0280 - Matsuyama/JP
  • 2 Department Of Pharmacy, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 3 Department Of Pharmacy, National Cancer Center Hospital, 104-0045 - Chuo-ku/JP
  • 4 Department Of Pharmacy, National Hospital Organization Kyushu Cancer Center, 811-1395 - Fukuoka/JP
  • 5 Department Of Pharmacy, National Hospital Organization Hokkaido Cancer Center, 003-0804 - Sapporo/JP
  • 6 Department Of General Internal Medicine, National Cancer Center Hospital, 104-0045 - Chuo-ku/JP
  • 7 Department Of Pharmacy, National Cancer Center Hospital East, 277-0882 - Kashiwa/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 447P

Background

Immune checkpoint inhibitor (ICI)-associated type 1 diabetes mellitus (T1DM) is a rare, but potentially life-threatening adverse event. However, clinical picture of this irAE remains largely unknown due to its low incidence. The aim of this study was to identify the characteristics and clinical course of ICI-associated T1DM for early detection and treatment.

Methods

We retrospectively reviewed 21 patients (pts) who developed T1DM during treatment with ICIs from October 2015 to March 2021 at the multicenter. The pts’clinical characteristics and laboratory and radiologic findings were collected.

Results

The characteristics were as follows: median age, 63 years (range, 32-75); male/female, 16/5; PS 0/1/3, 10/10/1; treatment Nivolumab/Nivolumab plus Ipilimumab, 14/7. The median time of clinical diagnosis was 3.3 months (range, 0.8-30.8), and the median number of ICI administrations before onset was 7 times (range, 1-57). Symptoms at the onset of T1DM included hyperglycemic symptoms (thirst, polydipsia, polyuria) in 14 pts (66.7%), abdominal symptoms in 11 pts (52.4%), flu-like symptoms in 6 pts (28.6%). The mean ± standard deviation or median glucose levels, HbA1c levels and serum C-peptide immunoreactivity levels at diagnosis were 556±336 mg/dL, 7.7±1.4 % and 0.40 ng/mL (range, 0.03-5.50), respectively. Diabetic ketoacidosis (DKA) was described in 9 pts (42.9%) and their median arterial pH was 7.190 (range, 7.019-7.373). Anti-glutamic acid decarboxylase antibodies were tested in 20 pts and were positive in 3 pts (15.0%). Of the 22 pts, 7 pts (33.3%) met the criteria of fulminant T1DM.

Conclusions

Patients with T1DM induced by ICIs showed similar symptoms to those of general T1DM, but those were not always present in each case. Of note, in about 60% of the cases the diagnosis of T1DM was made before the development of overt DKA. In some cases, moderate hyperglycemia found incidentally at the scheduled visit led to the diagnosis of T1DM. Therefore, routine measurement of plasma glucose levels should be mandatory for early detection of ICI-associated T1DM and if suspected, prompt initiation of insulin treatment should be considered to avoid life-threatening metabolic alterations.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Japanese Society of Pharmaceutical Oncology.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

  • Analytics cookies help us improve our website by collecting and reporting information on its usage.

  • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.